- Home
- MRSN vs KPTI Comparison
MRSN vs KPTI Comparison
Compare MRSN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- KPTI
- Stock Information
- Founded
- MRSN 2001
- KPTI 2008
- Country
- MRSN United States
- KPTI United States
- Employees
- MRSN N/A
- KPTI N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- KPTI Health Care
- Exchange
- MRSN Nasdaq
- KPTI Nasdaq
- Market Cap
- MRSN 36.4M
- KPTI 33.6M
- IPO Year
- MRSN 2017
- KPTI 2013
- Fundamental
- Price
- MRSN $0.35
- KPTI $4.95
- Analyst Decision
- MRSN Buy
- KPTI Strong Buy
- Analyst Count
- MRSN 3
- KPTI 5
- Target Price
- MRSN $4.00
- KPTI $61.00
- AVG Volume (30 Days)
- MRSN 3.1M
- KPTI 161.4K
- Earning Date
- MRSN 05-08-2025
- KPTI 05-07-2025
- Dividend Yield
- MRSN N/A
- KPTI N/A
- EPS Growth
- MRSN N/A
- KPTI N/A
- EPS
- MRSN N/A
- KPTI N/A
- Revenue
- MRSN $40,497,000.00
- KPTI $145,237,000.00
- Revenue This Year
- MRSN N/A
- KPTI $4.87
- Revenue Next Year
- MRSN N/A
- KPTI $16.29
- P/E Ratio
- MRSN N/A
- KPTI N/A
- Revenue Growth
- MRSN 9.88
- KPTI N/A
- 52 Week Low
- MRSN $0.26
- KPTI $3.51
- 52 Week High
- MRSN $3.83
- KPTI $21.30
- Technical
- Relative Strength Index (RSI)
- MRSN 44.90
- KPTI 48.29
- Support Level
- MRSN $0.31
- KPTI $3.83
- Resistance Level
- MRSN $0.40
- KPTI $4.36
- Average True Range (ATR)
- MRSN 0.05
- KPTI 0.43
- MACD
- MRSN 0.01
- KPTI 0.22
- Stochastic Oscillator
- MRSN 68.09
- KPTI 91.72
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.